Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA Task Force report.

OBJECTIVES A growing number of prospective clinical trials include economic end points. Recognizing the variation in methodology and reporting of these studies, the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) chartered the Task Force on Good Research Practices: Randomized Clinical Trials-Cost-Effectiveness Analysis. Its goal was to develop a guidance document for designing, conducting, and reporting cost-effectiveness analyses conducted as a part of clinical trials. METHODS Task force cochairs were selected by the ISPOR Board of Directors. Cochairs invited panel members to participate. Panel members included representatives from academia, the pharmaceutical industry, and health insurance plans. An outline and a draft report developed by the panel were presented at the 2004 International and European ISPOR meetings, respectively. The manuscript was then submitted to a reference group for review and comment. RESULTS The report addresses issues related to trial design, selecting data elements, database design and management, analysis, and reporting of results. Task force members agreed that trials should be designed to evaluate effectiveness (rather than efficacy), should include clinical outcome measures, and should obtain health resource use and health state utilities directly from study subjects. Collection of economic data should be fully integrated into the study. Analyses should be guided by an analysis plan and hypotheses. An incremental analysis should be conducted with an intention-to-treat approach. Uncertainty should be characterized. Manuscripts should adhere to established standards for reporting results of cost-effectiveness analyses. CONCLUSIONS Trial-based cost-effectiveness studies have appeal because of their high internal validity and timeliness. Improving the quality and uniformity of these studies will increase their value to decision makers who consider evidence of economic value along with clinical efficacy when making resource allocation decisions.

[1]  M. Boyle,et al.  Multiattribute and Single‐Attribute Utility Functions for the Health Utilities Index Mark 3 System , 2002, Medical care.

[2]  Lisa M. Schwartz,et al.  Assessing Values for Health: Numeracy Matters , 2001, Medical decision making : an international journal of the Society for Medical Decision Making.

[3]  W. Manning,et al.  The logged dependent variable, heteroscedasticity, and the retransformation problem. , 1998, Journal of health economics.

[4]  S. van der Linden,et al.  Responsiveness of the core set, response criteria, and utilities in early rheumatoid arthritis , 2000, Annals of the rheumatic diseases.

[5]  Other World development indicators 2001 , 2001 .

[6]  W Sumner,et al.  U-titer: a utility assessment tool. , 1991, Proceedings. Symposium on Computer Applications in Medical Care.

[7]  J. MacKinnon,et al.  Estimation and inference in econometrics , 1994 .

[8]  ANALYZING DIFFERENCES IN THE COSTS OF TREATMENT ACROSS CENTERS WITHIN ECONOMIC EVALUATIONS , 2001, International Journal of Technology Assessment in Health Care.

[9]  I. White,et al.  Choice of test for comparing two groups, with particular application to skewed outcomes , 2003, Statistics in medicine.

[10]  A. Kasuya EuroQol--a new facility for the measurement of health-related quality of life. , 1990, Health policy.

[11]  Bernie J. O'Brien,et al.  In Search of Power and Significance: Issues in the Design and Analysis of Stochastic Cost-Effectiveness Studies in Health Care , 1994, Medical care.

[12]  R. Deyo,et al.  The practicality and validity of directly elicited and SF-36 derived health state preferences in patients with low back pain. , 2002, Health economics.

[13]  W. Manning,et al.  Estimating Log Models: To Transform or Not to Transform? , 1999, Journal of health economics.

[14]  Robert L. Mason,et al.  Statistical Principles in Experimental Design , 2003 .

[15]  M. Smithson Statistics with confidence , 2000 .

[16]  J. Schafer Multiple imputation: a primer , 1999, Statistical methods in medical research.

[17]  F. Salaffi,et al.  Responsiveness of Health Status Measures and Utility-based Methods in Patients with Rheumatoid Arthritis , 2002, Clinical Rheumatology.

[18]  Morris Meisner,et al.  Power and Sample Size in Cost- Effectiveness Analysis , 1999, Medical decision making : an international journal of the Society for Medical Decision Making.

[19]  Seymour Geisser,et al.  Statistical Principles in Experimental Design , 1963 .

[20]  A Briggs,et al.  The Distribution of Health Care Costs and Their Statistical Analysis for Economic Evaluation , 1998, Journal of health services research & policy.

[21]  P Carlsson,et al.  Resource costing for multinational neurologic clinical trials: methods and results. , 1998, Health economics.

[22]  R. Willke,et al.  Estimating country-specific cost-effectiveness from multinational clinical trials. , 1998, Health economics.

[23]  D. Torgerson,et al.  Converting international cost effectiveness data to UK prices , 2002, BMJ : British Medical Journal.

[24]  A H Briggs,et al.  Handling uncertainty when performing economic evaluation of healthcare interventions. , 1999, Health technology assessment.

[25]  K. Cook,et al.  A Trial for Comparing Methods for Eliciting Treatment Preferences From Men With Advanced Prostate Cancer: Results From the Initial Visit , 2000, Medical care.

[26]  Andrew Briggs,et al.  The Design and Analysis of Stochastic Cost-Effectiveness Studies for the Evaluation of Health Care Interventions , 2001 .

[27]  Richard Willke,et al.  Variability of cost-effectiveness estimates for pharmaceuticals in Western Europe: lessons for inferring generalizability. , 2005, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[28]  Anthony O'Hagan,et al.  Assessing and comparing costs: how robust are the bootstrap and methods based on asymptotic normality? , 2003, Health economics.

[29]  S. Wilson Methods for the economic evaluation of health care programmes , 1987 .

[30]  M. Stano,et al.  Adjusting to changes in health: implications for cost-effectiveness analysis. , 2004, Journal of health economics.

[31]  M. Weinstein,et al.  Economic Evaluation Alongside Multinational Clinical Trials: Study Considerations for GUSTO iib , 1997, International Journal of Technology Assessment in Health Care.

[32]  A. Gnanasakthy,et al.  COMPARISON OF HOSPITAL COSTING METHODS IN AN ECONOMIC EVALUATION OF A MULTINATIONAL CLINICAL TRIAL , 2003, International Journal of Technology Assessment in Health Care.

[33]  A. Williams EuroQol : a new facility for the measurement of health-related quality of life , 1990 .

[34]  M. Gold Cost-effectiveness in health and medicine , 2016 .

[35]  R M Kaplan,et al.  A general health policy model: update and applications. , 1988, Health services research.

[36]  M C Weinstein,et al.  Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine. , 1996, JAMA.

[37]  Michael Drummond,et al.  Assessing the appropriateness of combining economic data from multinational clinical trials , 2003, Statistics in medicine.

[38]  Douglas G. Altman,et al.  Statistics Notes: Transforming data , 1996 .

[39]  M. Drummond,et al.  Issues in the Cross-National Assessment of Health Technology , 1992, International Journal of Technology Assessment in Health Care.

[40]  J. Kalbfleisch,et al.  The Statistical Analysis of Failure Time Data , 1980 .

[41]  M. Kenward,et al.  An Introduction to the Bootstrap , 2007 .

[42]  T O Jefferson,et al.  Guidelines for authors and peer reviewers of economic submissions to the BMJ , 1996, BMJ.

[43]  Donald Hedeker,et al.  Application of random-efiects pattern-mixture models for miss-ing data in longitudinal studies , 1997 .

[44]  R Peto,et al.  Large-scale randomized evidence: large, simple trials and overviews of trials. , 1993, Annals of the New York Academy of Sciences.

[45]  N. Blomqvist,et al.  Estimating confidence intervals for cost-effectiveness ratios: an example from a randomized trial. , 1998, Statistics in medicine.

[46]  S. Thompson,et al.  Analysis of cost data in randomized trials: an application of the non-parametric bootstrap. , 2000, Statistics in medicine.

[47]  D. Patrick,et al.  Health Status and Health Policy: Quality of Life in Health Care Evaluation and Resource Allocation , 1993 .

[48]  Anthony O'Hagan,et al.  On estimators of medical costs with censored data. , 2004, Journal of health economics.

[49]  George W. Torrance,et al.  Application of Multi-Attribute Utility Theory to Measure Social Preferences for Health States , 1982, Oper. Res..

[50]  J. Heyse,et al.  A regression-based method for estimating mean treatment cost in the presence of right-censoring. , 2000, Biostatistics.

[51]  Peter C Austin,et al.  A comparison of methods for analyzing health-related quality-of-life measures. , 2002, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[52]  D. Hosmer,et al.  Applied Logistic Regression , 1991 .

[53]  D. Meltzer,et al.  Accounting for Future Costs in Medical Cost-Effectiveness Analysis , 1997, Journal of health economics.

[54]  J. Clouse,et al.  Implications of controlling for comorbid conditions in cost-of-illness estimates: a case study of osteoarthritis from a managed care system perspective. , 2001, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[55]  B. O'brien,et al.  Economic evaluation of pharmaceuticals. Frankenstein's monster or vampire of trials? , 1996, Medical care.

[56]  S M Gray,et al.  Estimating a treatment effect from multidimensional longitudinal data. , 1998, Biometrics.

[57]  L Goldman,et al.  Stability of Time-tradeoff Utilities in Survivors of Myocardial Infarction , 1993, Medical decision making : an international journal of the Society for Medical Decision Making.

[58]  M J Al,et al.  Sample size calculation in economic evaluations. , 1998, Health economics.

[59]  John C. Hershey,et al.  Carrier Screening for Cystic Fibrosis , 1998, Medical decision making : an international journal of the Society for Medical Decision Making.

[60]  M. Sculpher,et al.  Representing uncertainty: the role of cost-effectiveness acceptability curves. , 2001, Health economics.

[61]  Bartlett Ms The use of transformations. , 1947 .

[62]  M Johannesson,et al.  A Note on Confidence Intervals in Cost-Effectiveness Analysis , 1998, International Journal of Technology Assessment in Health Care.

[63]  U. Gerdtham,et al.  Conversion factor instability in international comparisons of health care expenditure. , 1991, Journal of health economics.

[64]  E. Feuer,et al.  Estimating medical costs from incomplete follow-up data. , 1997, Biometrics.

[65]  N. Freemantle,et al.  Use of health‐related quality of life in prescribing research. Part 2: methodological considerations for the assessment of health‐related quality of life in clinical trials , 2004, Journal of clinical pharmacy and therapeutics.

[66]  W. Busse,et al.  Country-specific cost-effectiveness of early intervention with budesonide in mild asthma , 2004, European Respiratory Journal.

[67]  A A Stinnett,et al.  Net Health Benefits , 1998, Medical decision making : an international journal of the Society for Medical Decision Making.

[68]  John Mullahy,et al.  Net Health Benefits: A New Framework for the Analysis of Uncertainty in Cost-Effectiveness Analysis , 1998 .

[69]  M J Al,et al.  Costs, effects and C/E-ratios alongside a clinical trial. , 1994, Health economics.

[70]  D G Altman,et al.  Statistics Notes: The use of transformation when comparing two means , 1996, BMJ.

[71]  J M Bland,et al.  Transforming data. , 1996, BMJ.

[72]  A. Mcguire,et al.  Centre-specific or average unit costs in multi-centre studies? Some theory and simulation. , 2000, Health economics.

[73]  Anastasios A Tsiatis,et al.  Median Regression with Censored Cost Data , 2002, Biometrics.

[74]  M A Koopmanschap,et al.  Analysis of costs and cost-effectiveness in multinational trials. , 2001, Health policy.

[75]  A. Ludbrook,et al.  Comparing costing results in across country economic evaluations: the use of technology specific purchasing power parities. , 2005, Health economics.

[76]  Daniel Polsky,et al.  Design and analysis of unit cost estimation studies: How many hospital diagnoses? How many countries? , 2003, Health economics.

[77]  S. Ramsey,et al.  Design issues for conducting cost-effectiveness analyses alongside clinical trials. , 2001, Annual review of public health.

[78]  P. Dolan,et al.  Modeling valuations for EuroQol health states. , 1997, Medical care.

[79]  P. O'Byrne,et al.  Design and analytic considerations in determining the cost-effectiveness of early intervention in asthma from a multinational clinical trial. , 2001, Controlled Clinical Trials.

[80]  B. O'brien,et al.  A tale of two (or more) cities: geographic transferability of pharmacoeconomic data. , 1997, The American journal of managed care.

[81]  Orton,et al.  Multiple Imputation in Practice , 2001 .

[82]  S. Thompson,et al.  How should cost data in pragmatic randomised trials be analysed? , 2000, BMJ : British Medical Journal.

[83]  鳥居 泰彦,et al.  世界経済・社会統計 = World development indicators , 1998 .

[84]  R D Etzioni,et al.  On the use of survival analysis techniques to estimate medical care costs. , 1999, Journal of health economics.

[85]  A. Mcguire,et al.  Estimating medical care costs under conditions of censoring. , 2004, Journal of health economics.

[86]  K. Schulman,et al.  The economic evaluation of the FIRST study: design of a prospective analysis alongside a multinational phase III clinical trial. Flolan International Randomized Survival Trial. , 1996, Controlled clinical trials.

[87]  D. Feeny,et al.  Multiattribute utility function for a comprehensive health status classification system. Health Utilities Index Mark 2. , 1996, Medical care.

[88]  K. Schulman,et al.  Results of the Economic Evaluation of the FIRST Study: A Multinational Prospective Economic Evaluation , 1996, International Journal of Technology Assessment in Health Care.

[89]  G. Torrance Multi-attribute preference functions for a comprehensive health status classification system , 1992 .

[90]  Milton C. Weinstein,et al.  Recommendations for Reporting Cost-effectiveness Analyses , 1996 .

[91]  M. Weinstein,et al.  Theoretical Foundations of Cost-Effectiveness Analysis , 1996 .

[92]  Andrew Briggs,et al.  Missing... presumed at random: cost-analysis of incomplete data. , 2003, Health economics.

[93]  Milton C Weinstein,et al.  Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices--Modeling Studies. , 2003, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[94]  S G Thompson,et al.  Analysis and interpretation of cost data in randomised controlled trials: review of published studies , 1998, BMJ.

[95]  Nicole A. Lazar,et al.  Statistical Analysis With Missing Data , 2003, Technometrics.

[96]  M H Liang,et al.  Stability and responsiveness of utility measures. , 1994, Medical care.

[97]  Grazyna Adamiak,et al.  Methods for the economic evaluation of health care programmes, 3rd ed , 2006 .

[98]  M. Gardner,et al.  Confidence intervals rather than P values: estimation rather than hypothesis testing. , 1986, British medical journal.

[99]  M. Gold,et al.  Panel on cost-effectiveness in health and medicine. , 1996, Medical care.

[100]  D Y Lin,et al.  Incremental net benefit in randomized clinical trials , 2001, Statistics in medicine.